Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

On Monday, Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin condition characterized by painful, recurrent boil-like lumps, often in areas where skin rubs together like the armpits and groin, that can lead to abscesses and scarring.

Also Read: Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg).

A significantly higher proportion of patients treated with ...